The DxI 9000 Analyzer efficiency unlocks powerful time savings with high sensitivity detection potential to the zeptomole level and precision powers a growing range of immunoassay tests to meet current and future needs.

Beckman Coulter’s DxI 9000 Access Immunoassay Analyzer is designed to achieve faster throughput, employ an enhanced chemiluminescent substrate (Lumi-Phos PRO), deliver shorter turnaround times, run more tests per reagent pack, and provide improved user workflows, when compared to the legacy Access UniCel DxI 800 Immunoassay System. The ...

Jul 25, 2023 · The DxI 9000 Analyzer has shown capability to develop increasingly sensitive and clinically relevant assays enabling the platform to keep pace with tomorrow’s testing requirements as healthcare providers and pharmaceutical companies …

The DxI 9000 is the next generation automated access immunoassay analyzer for mid to ultra high-volume laboratories. Users will appreciate the analyzer's throughput (450 tests/h), the absence of daily maintenance (ZeroDaily maintenance), but also the PrecisionVision technology

ANAHEIM, Calif., July 25, 2023 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, today revealed for the first time in North America the DxI 9000 Access Immunoassay Analyzer,...

ROME, May 15, 2023 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, today unveiled the DxI 9000 Access Immunoassay Analyzer, the most productive immunoassay analyzer per footprint....

ROME, May 15, 2023 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, today unveiled the DxI 9000 Access Immunoassay Analyzer, the most productive immunoassay analyzer per footprint. The DxI 9000 Analyzer can run …

The DxI 9000 Immunoassay Analyzer sets a new standard for today’s busy labs. With meaningful innovations that amplify your impact, liberate you from the laborious, and power your performance across your health system, this high-throughput immunoassay analyzer …

Beckman Coulter’s N-terminal pro b-type natriuretic peptide (NT-proBNP) assay is now available on the DxI 9000 Immunoassay Analyzer for detection of heart failure and cardiac dysfunction biomarkers in line with both European Society of Cardiology guidelines and the American College of Cardiology/American Heart Association guidelines.

The DxI 9000 Aalyzer assays “leads the diagnostic landscape” for six sigma performance under the new CLIA proficiency testing rules against competitive immunoassay analyzers from companies including Abbott, Roche, and Siemens